Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived Adult Stem Cells at the World Conference on Regenerative Medicine

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it will chair a panel entitled: "Placenta-Derived Adult Stem Cells as an Allogeneic Alternative to Mesenchymal Stromal Cells (MSCs)” at the World Conference on Regenerative Medicine at the Congress Center Leipzig, in Leipzig, Germany. Edwin M. Horwitz, M.D., Ph.D., chairman of Pluristem’s scientific advisory board, will present, as the keynote speaker, the clinical landscape of MSCs and Pluristem’s clinical trial for the treatment of critical limb ischemia (CLI), an example of non-HLA matched allogeneic local delivery of placenta-derived MSCs, at 10:45 a.m. CET, Oct. 30, 2009.

"Placenta-derived stem cells may offer a viable allogeneic alternative to MSCs from bone marrow, cord blood and other sources,” said Dr. Horwitz. "Clinical trials with Pluristem’s placental expanded cells may eventually demonstrate that placenta-derived stromal cells are a viable treatment for a variety of degenerative, ischemic and autoimmune disorders, including CLI.”

Participants on the panel will include Hans-Dieter Volk, Ph.D., professor of immunology and chair of the Institute of Medical Immunology Charité - Universitätsmedizin Berlin and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), who will present on the immunological behavior of MSCs. Frida Grynspan, Ph.D., Pluristem’s vice president of research & development, will present on the placenta as an alternative and preferential source of MSCs.

The World Conference on Regenerative Medicine 2009 will be held on Oct. 29-31, 2009, in Leipzig, Germany. The Fraunhofer Institute for Cell Therapy and Immunology is the organizer and host of this event and the Translational Center for Regenerative Medicine (TRM) Leipzig is the co-organizer. Over 1,000 participants from research institutes, clinics and industry are expected to participate in the conference. Topics include: stem cells, tissue engineering, technology development, immunology & signaling and regulatory affairs. For more information on this event, please visit: www.wcrm-leipzig.com.

About Pluristem

Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.

See our product animation on YouTube: Animation, the content of which is not part of this press release.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we say that Placenta-derived stem cells may offer a viable allogeneic alternative to MSCs from bone marrow, cord blood and other sources, or that clinical trials with Pluristem’s placental expanded cells may eventually demonstrate that placenta-derived stromal cells are a viable treatment for a variety of degenerative, ischemic and autoimmune disorders, including CLI, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.